Welcome to our dedicated page for Sarepta Therapeutics SEC filings (Ticker: SRPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sarepta Therapeutics, Inc.'s SEC filings document an operating biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under SRPT. Form 8-K reports furnish quarterly and annual financial results, product revenue disclosures for ELEVIDYS and PMO therapies, and clinical or regulatory updates for Duchenne muscular dystrophy treatments and siRNA pipeline programs.
Other filings cover proxy governance, executive compensation, equity-award plans and leadership-transition disclosures. Material-event reports also describe capital-structure actions, including exchange agreements for convertible senior notes, issuance of new convertible notes, common stock consideration and related indenture terms.
Sarepta Therapeutics, Inc. president of R&D and Tech Ops Louise Rodino-Klapac reported equity compensation activity. On March 1, 2026, 8,125 Performance Stock Units previously earned under a March 1, 2024 PSU award vested and were converted into the same number of common shares, based on the compensation committee’s milestone achievement determination. On March 2, 2026, the company withheld 3,718 and 767 common shares, respectively, at $16.20 per share to cover tax withholding obligations related to the vesting of PSU and RSU awards, leaving Rodino-Klapac with 227,670 directly held common shares.
Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan exercised stock options and acquired additional common shares. On February 26, 2026, he exercised options for 2,069 shares and 5,381 shares of common stock at an exercise price of $13.71 per share. These transactions increased his directly held common stock to 200,750 shares, according to the filing footnote, and involved no reported open-market sales.
Sarepta Therapeutics is a commercial-stage biopharma company focused on RNA-targeted drugs, siRNA therapies and gene therapies for rare neuromuscular diseases, led by Duchenne muscular dystrophy.
The company sells four approved Duchenne products—EXONDYS 51, VYONDYS 53, AMONDYS 45 and the gene therapy ELEVIDYS—and recorded $1,864.3 million in product net revenues for the year ended December 31, 2025, up from $1,788.0 million in 2024 and $1,144.9 million in 2023.
2025 brought significant challenges. Top-line results from the ESSENCE confirmatory trial for VYONDYS 53 and AMONDYS 45 did not meet the primary endpoint, and Sarepta plans further FDA discussions on their approval status. ELEVIDYS was temporarily suspended in the U.S. after serious safety events, later resuming only for ambulatory patients and gaining a boxed warning for acute liver injury and acute liver failure while the non-ambulatory indication was removed from labeling.
The FDA also placed a clinical hold on Sarepta’s LGMD gene therapy trials after a patient death, with SRP‑9003’s path now contingent on additional sirolimus data. At the same time, Sarepta entered a large siRNA collaboration with Arrowhead, paying a $500.0 million upfront fee plus substantial milestones and royalties, and continues to partner with Roche on ELEVIDYS ex-U.S. and with Catalent and Aldevron for manufacturing.
Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan reported an equity compensation transaction involving performance stock units. He acquired 1,875 performance stock units on February 25, 2026 as a grant/award, bringing his directly held performance stock units to 8,125.
According to the disclosure, these 1,875 shares represent units earned under a performance stock unit award originally granted on March 1, 2024, based on the compensation committee’s determination of the company’s achievement of specified milestones. The earned units are scheduled to vest on March 1, 2026, if he continues to provide service to the company through that date.
Sarepta Therapeutics, Inc. reported that executive Louise Rodino-Klapac, President of R&D and Tech Ops, acquired 1,875 Performance Stock Units (PSUs) on the basis of a prior equity award. These PSUs were earned under a PSU grant originally awarded on March 1, 2024.
The number of PSUs earned reflects the compensation committee’s assessment of the company’s achievement of specified milestones in that award. Following this transaction, Rodino-Klapac holds a total of 8,125 PSUs. The earned PSUs are scheduled to vest on March 1, 2026, provided she continues to serve the company through that date.
Sarepta Therapeutics, Inc. reported that Chief Executive Officer Douglas Ingram has decided to retire. On February 25, 2026, he informed the company that he plans to step down by the end of 2026 or once a successor is appointed.
The company has begun a formal search process, considering both internal and external candidates to identify its next CEO. This filing does not discuss changes to the company’s strategy or operations, focusing solely on the planned leadership transition timeline.
Sarepta Therapeutics reported strong 2025 revenue growth but a sharp swing to losses as it invested heavily in gene therapy and RNAi programs. Full-year revenue rose to $2,198.2M from $1,902.0M, driven by ELEVIDYS and higher collaboration and manufacturing revenue, including milestones from Roche and Japan.
Despite this, Sarepta posted a GAAP net loss of $713.4M versus $235.2M of net income in 2024, with diluted EPS moving from $2.34 to a loss of $7.13. The decline reflects a surge in cost of sales, including a $165.3M inventory reserve and additional write-offs, plus research and development expenses of $1,522.1M tied to the Arrowhead DM1 collaboration and milestones.
Year-end cash, cash equivalents and investments were $953.8M. Sarepta refinanced $291.4M of 2027 convertible notes into 2030 notes with cash, reducing near-term maturities. Management highlighted positive three-year EMBARK data for ELEVIDYS, launch in Japan via Chugai, and advancement of multiple siRNA programs, and said it anticipates remaining profitable and cash-flow positive in 2026.
AQR Capital Management Holdings, LLC and AQR Capital Management, LLC report beneficial ownership of 8,104,869 shares of Sarepta Therapeutics, Inc. common stock, representing 7.73 % of the class as of 12/31/2025.
The position includes Convertible Notes representing 308,334 shares of common stock. The AQR entities report shared voting and shared dispositive power over all 8,104,869 shares, with no sole voting or dispositive authority.
They certify the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Sarepta Therapeutics. AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC.
Sarepta Therapeutics, Inc. filed a Form 13F as an institutional investment manager. The filing lists 1 Form 13F information table entry and reports a total table value of $0. The report is signed by Ryan Wong, Executive Vice President and Chief Financial Officer, dated 02-12-2026.
Sarepta Therapeutics director Claude Nicaise exercised stock options and adjusted his shareholdings. On January 29, 2026, he exercised 10,500 stock options at $13.71 per share, receiving 10,500 shares of common stock.
On the same date, 6,780 common shares were withheld by Sarepta, noted as satisfying payment of the option exercise price. After these transactions, Nicaise directly owned 31,532 shares of Sarepta common stock.